Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic.

By R. Marx. Journal of oral and maxillofacial surgery, 2003

2,974 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. (2012, background): “Initial reports of ONJ suggested a highly morbid and untreatable condition [31].”
Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society* Clinical Practice Guideline. (2019, background): “(1-84), romosozumab, strontium ranelate, and lasofoxifene (Fig.”
Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. (2005, background): “Painful exposure of bone in the mandible and maxilla of patients receiving the bisphosphonates pamidronate (Aredia; Novartis Pharmaceuticals, East Hanover, NJ) and zoledronate (Zometa; Novartis Pharmaceuticals) was first reported by Marx in 2003.(1) Since then, several authors have reported addition”
Denosumab and bisphosphonates: different mechanisms of action and effects. (2011, background): “Bisphosphonate-related ONJ was originally reported in patients receiving treatment to prevent hypercalcemia or other skeletal complications of cancer [169,170].”